EFFICACY OF GALCANEZUMAB IN PATIENTS WHO FAILED TO RESPOND TO PREVENTIVES PREVIOUSLY: RESULTS FROM EVOLVE-1, EVOLVE-2 AND REGAIN STUDIES

被引：0
|
作者：
Zhang, Q. [1 ]
Ruff, D. D. [1 ]
Pearlman, E. M. [2 ]
Govindan, S. [3 ]
Aurora, S. [4 ]
机构：
[1] Eli Lilly & Co, Stat Neurosci LTC, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Migraine Headache, Indianapolis, IN 46285 USA
[3] Eli Lilly & Co, Med Writing, LCCI Biometr, Bangalore, Karnataka, India
[4] Eli Lilly & Co, Gakanezumab Launch, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS2018-0
引用
收藏
页码：51 / 52
页数：2
相关论文
共 50 条
  • [21] Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies
    Smitherman, Todd A.
    Tietjen, Gretchen E.
    Schuh, Kory
    Skljarevski, Vladimir
    Lipsius, Sarah
    D'Souza, Deborah N.
    Pearlman, Eric M.
    HEADACHE, 2020, 60 (10): : 2202 - 2219
  • [22] Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
    Jessica Ailani
    J. Scott Andrews
    Mallikarjuna Rettiganti
    Robert A. Nicholson
    The Journal of Headache and Pain, 2020, 21
  • [23] Phase 3 studies (EVOLVE-1 & EVOLVE-2) of galcanezumab in episodic migraine: subgroup analyses of efficacy by low-versus high-frequency of migraine headaches
    Silberstein, Stephen
    Stauffer, Virginia L.
    Day, Katie
    Zhang, Qi
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [24] Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
    Ailani, Jessica
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Nicholson, Robert A.
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [25] 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies
    Rosen, Noah
    Pearlman, Eric
    Ruff, Dustin
    Day, Kathleen
    Nagy, Abraham Jim
    HEADACHE, 2018, 58 (09): : 1347 - 1357
  • [26] Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies
    Oakes, Tina M.
    Kovacs, Richard
    Rosen, Noah
    Doty, Erin
    Kemmer, Phebe
    Aurora, Sheena K.
    Camporeale, Angelo
    HEADACHE, 2020, 60 (01): : 110 - 123
  • [27] Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2
    Macgregor, E. Anne
    Okonkwo, Rose
    Detke, Holland C.
    Polavieja, Pepa
    Fernandes, Maria S.
    Pavlovic, Jelena M.
    HEADACHE, 2024, 64 (02): : 179 - 187
  • [28] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) (vol 20, 75, 2019)
    Silberstein, Stephen D.
    Stauffer, Virginia L.
    Day, Katie A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01):
  • [29] Efficacy of galcanezumab for migraine prevention in patients with a medical history of anxiety and/or depression: a post hoc analysis of the phase 3, randomized, double-blind, placebo-controlled REGAIN, and pooled EVOLVE-1 and EVOLVE-2 studies (vol 60, pg 2202, 2020)
    Smitherman, T. A.
    HEADACHE, 2022, 62 (01): : 114 - 116
  • [30] Changes in Patient Functioning and Disability: Results from Two Phase 3 Double-Blind Placebo-Controlled Clinical Trials Evaluating Galcanezumab for Episodic Migraine Prevention (EVOLVE-1 and EVOLVE-2)
    Ford, J.
    Ayer, D.
    Zhang, Q.
    Carter, J.
    Skljarevski, V
    Aurora, S.
    HEADACHE, 2018, 58 : 171 - 172
12345